{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-174947","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.446592+00:00","generated_at":"2026-05-17T17:36:07.960696+00:00","sec_items":["1.01","2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"REGENXBIO amends AbbVie deal; restructures $200M milestones, starts DR pivotal; Q2 net loss $70.9M","bullets":["Amendment to AbbVie collaboration: $100M milestone upon first pt dosed in Phase IIb/III DR trial, additional $100M upon first pt in Phase III.","REGENXBIO to pay costs for Phase IIb of that trial; AbbVie to fund new Phase III wAMD study (ACHIEVE).","Q2 net loss $70.9M ($1.38/share) vs $53.0M loss year ago; revenue $21.4M, down from $22.3M.","Cash $363.6M at June 30, 2025; expects to fund operations into early 2027.","RGX-202 Duchenne pivotal enrollment accelerated, to complete Oct 2025; topline data 1H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-174947","json":"https://secwatch.observer/filing/0001193125-25-174947.json","markdown":"https://secwatch.observer/filing/0001193125-25-174947.md","text":"https://secwatch.observer/filing/0001193125-25-174947.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000119312525174947/0001193125-25-174947-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000119312525174947/rgnx-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:36:07.960696+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}